Genmab — Juli 2018

[gentogen]

NICE: there was a statistically significant
(p<0.0001) increase in progression-free survival with daratumumab plus
bortezomib and dexamethasone (median survival 26 months) compared
with bortezomib plus dexamethasone (median survival 8 months; hazard
ratio [HR] 0.23, 95% confidence interval [CI] 0.16 to 0.33), after a median
follow-up of 27 months (pre-specified interim analysis).

[gentogen]

Men ikke NICE nok til NICE!

[gentogen]

The
committee noted that the available data showed that daratumumab plus
bortezomib and dexamethasone reduced the risk of death by 50%
compared with bortezomib plus dexamethasone (HR 0.50, 95% CI
0.30 to 0.84, p=0.008).

[Plimsoller]

Siden findes ikke

(borsen.dk)

[E_L]

Genmab, Immatics Launch Up-to-$2.8B+ Cancer Immunotherapy Partnership https://www.genengnews.com/gen-news-highlights/genmab-immatics-launch-up-to-28b-cancer-immunotherapy-partnership/81256019

[E_L]

usefull tweet EPVantage https://twitter.com/EPVantage/status/1017421620305170432

[E_L]

Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies - labiotech - https://labiotech.eu/genmab-immatics-cancer-immunotherapy/

[royal]

Måske den nye DARA?

[E_L]

AND den nye CAR-T

[royal]

Maybe, but it will take some years. Nice they make the money work.

[E_L]

WAY too early to say anything offcourse, but it is a sizeable deal, you dont do that without good hope of success

[E_L]

---

[E_L]

Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors - http://investor.seagen.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2357993

[E_L]

---

[peter12]

Unum Therapeutics to Present Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the American Society of Hematology (ASH) Summit on Emerging Immunotherapies for Hematological Diseases https://globenewswire.com/news-release/2018/07/12/1536414/0/en/Unum-Therapeutics-to-Present-Pre-Clinical-Data-on-its-Antibody-Coupled-T-Cell-Receptor-ACTR-Platform-at-the-American-Society-of-Hematology-ASH-Summit-on-Emerging-Immunotherapies-fo.html

[Thomas]

Vedr SG/Genmab Phase 2: Op til 200 patienter i 4 forskellige grene, dvs 50 patienter i hver gren - kan man virkelig søge godkendelse på et studie med 50 mand?

[Solsen]

De udvider
om nødvendligt

[Plimsoller]

God morgen

[Parasitism]

God morgen

[Helge_LarsenPI-redaktør]

God morgen.